Altered bone metabolism in inflammatory bowel disease

Area of Science:

• Gastroenterology
• Endocrinology
• Rheumatology

Background:

• Reduced bone mineral density is a known complication in patients with inflammatory bowel disease (IBD).
• The specific mechanisms underlying bone disease in IBD remain incompletely understood.

Purpose of the Study:

• To investigate the underlying mechanisms contributing to bone disease in patients diagnosed with inflammatory bowel disease.
• To correlate biochemical markers of bone metabolism with bone mineral density in IBD patients.

Main Methods:

• Assessed bone mineral density using peripheral quantitative computed tomography (pQCT) at the forearm in 90 IBD patients.
• Measured serum biochemical markers of bone metabolism, including osteocalcin and carboxyterminal cross-linked telopeptide of type I collagen (ICTP).

Main Results:

• Forty-five percent of IBD patients exhibited reduced bone density (Z score < -1).
• Elevated ICTP levels, indicating increased bone breakdown, were observed in 38% of patients and correlated with reduced bone density.
• Active IBD status and a history of active disease were associated with increased bone degradation markers.

Conclusions:

• Bone disease in IBD is multifactorial, involving direct inflammatory effects on bone, corticosteroid treatment side effects, and potential malabsorption leading to vitamin D deficiency.
• High inflammatory activity in IBD may directly induce bone degradation through unelucidated pathways.
• Increased bone turnover and degradation are significant concerns in IBD management, necessitating further research into therapeutic interventions.